Asano Yuka, Kashiwagi Shinichiro, Goto Wataru, Takada Koji, Morisaki Tamami, Takashima Tsutomu, Noda Satoru, Onoda Naoyoshi, Ohsawa Masahiko, Hirakawa Kosei, Ohira Masaichi
Dept. of Surgical Oncology, Osaka City University Graduate School of Medicine.
Gan To Kagaku Ryoho. 2016 Nov;43(12):2240-2242.
A goal for treating advanced disease is prolonging survival while maintaining a good quality of life(QOL). Eribulin chemotherapy may be suitable for this purpose. We report a case of advanced breast cancer with pathological complete response (pCR)obtained by eribulin chemotherapy. The patient was a 43-year-old woman who complained of a right mammary mass. A tumor measuring approximately 3 cm was palpated, and breast cancer was detected via ultrasound examination. Core needle biopsy indicated invasive ductal carcinoma based on histopathological findings. A metastasis to the supraclavicular lymph node was observed and was found to be malignant via fine-needle aspiration cytology. The patient was diagnosed with advanced breast cancer cT2N3M0, stage III C, Luminal B like. She underwent primary systemic therapy with 6 cycles of eribulin. The patient exhibited a clinical complete response to eribulin chemotherapy. Thereafter, a right mastectomy with level 3 axillary lymph node dissection was performed. Pathological diagnosis of the surgical specimen was pCR. At present, 3 years after surgery, the patient has no recurrence.
治疗晚期疾病的目标是在维持良好生活质量(QOL)的同时延长生存期。艾瑞布林化疗可能适用于此目的。我们报告一例晚期乳腺癌患者,通过艾瑞布林化疗获得了病理完全缓解(pCR)。该患者为一名43岁女性,主诉右乳肿块。触诊发现一个约3 cm的肿瘤,经超声检查确诊为乳腺癌。粗针活检根据组织病理学结果显示为浸润性导管癌。观察到锁骨上淋巴结转移,经细针穿刺细胞学检查发现为恶性。该患者被诊断为晚期乳腺癌cT2N3M0,ⅢC期,Luminal B型。她接受了6个周期的艾瑞布林一线全身治疗。患者对艾瑞布林化疗表现出临床完全缓解。此后,进行了右侧乳房切除术及腋窝三级淋巴结清扫术。手术标本的病理诊断为pCR。目前,术后3年,患者无复发。